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ABSTRACT 
 
  
The purpose of this IQP was to investigate stem cell types and applications, and their 
effects on society via ethics and legalities. From our research we conclude that embryonic stem 
cells (ESCs) have greater medical potential and future applications than adult stem cells (ASCs) 
due to their very strong differentiation advantage and ease of growth.  All 5 major world 
religions support ASC use, but working with ESCs is not accepted by some Christian groups. 
Based on our findings, we believe the current U.S. legislation recently enacted by President 
Obama should be extended to allow paid egg donors, as in Sweden and South Korea, and agree 
with its mandate to allow federal funding to support this promising technology.  
 3 
TABLE OF CONTENTS 
 
 
Signature Page ……………………………………………………………………..  1 
Abstract …………………………………………………………………………….  2 
Table of Contents …………………………………………………………………..  3 
Project Objective ……………………………………...……………………………  4 
Chapter-1:   Stem Cell Technology ……………...…………………………………  5 
Chapter-2:   Stem Cell Applications ..……………………………………………..  18 
Chapter-3:  Stem Cell Ethics ………………………………………………………  28 
Chapter-4:  Stem Cell Legalities …………………………………….…………….  36 
Project Conclusions …………………………………….……….…………………  46 
 4 
PROJECT OBJECTIVES 
 
 
 The goal of this IQP project was to explore the topic of stem cells, and to discuss the 
impact of this controversial new technology on society by investigating their ethics and 
legalities.  In Chapter-1 the various types of stem cells are introduced, the sources of each type 
are identified, and their abilities and functions are discussed.  Chapter-2’s objective is to show 
examples of animal experiments and human clinical trials to document where the technology 
currently stands with respect to societal benefits.  Chapter-3 shows the point of view on this new 
biomedical field from an ethical perspective. Chapter-4’s purpose is to document various U.S. 
and International laws that regulate stem cell uses. Finally, a conclusion is made by authors in 
order to share their thoughts and opinions about stem cells. 
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CHAPTER 1: STEM CELL TYPES AND SOURCES 
 
Batuhan Gizer 
 
 The human body is one of the most complex living entities that occupy this world.  
Different mechanisms in the human body require an enormous diversity of cells, including white 
blood cells, red blood cells, skin cells, nerve cells, stem cells, etc.  Most of these cells have 
specific predefined functions throughout their lives, and a limited lifespan.  However, stem cells 
do not follow this pattern; they can divide long-term, and depending on the type of stem cell, can 
differentiate to form almost any kind of cell in our body.  In other words, they are often termed 
the “master” cells.  But stem cells are not all alike, as some have the ability to form multiple cell 
types, while others can predominately form only one cell type.  So this chapter’s purpose is to 
document the different kinds of stem cells, and to discuss their potencies.  This topic is important 
for subsequent chapter discussions on stem cell uses, ethics, and government policies.   
 
Stem Cell Classification 
 
 Stem cells can broadly be divided into two main categories: adult stem cells (ASC’s) and 
embryonic stem (ES) cells (ProQuest, 2004).  As their names imply, ASCs are usually obtained 
from adult tissues, while ES cells are usually obtained from an embryo.  The ASC category often 
loosely includes umbilical cord blood as a source of hematopoietic stem cells, even though 
umbilical cord is not an adult tissue.   
Stem cells also can be classified based on their potencies.  Newly fertilized eggs through 
the 8–cell stage are considered totipotent, and can create any cell in the body plus the placenta.  
ES cells are considered pluripotent, and can differentiate to form any cell type except the 
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placenta.  A common misconception is that ES cells are totipotent, but ES cells cannot form the 
placenta so they cannot be totipotent.  ES cells are obtained from the inner cell mass of a 
blastocyst embryo.  The isolation process kills the embryo, which produces strong ethical 
controversies in the medical use of this type of stem cell.  But ES cells are also the most 
promising stem cell type in medicine, and they have enormous potential to cure some of the 
deadliest diseases since they can differentiate into huge variety of tissues.   Multipotent cells can 
form several types of related cells.  A good example in this category is a hematopoietic stem cell 
that can form multiple types of blood cells.  Another example of multipotent stem cells is 
neuronal stem cells which can form neurons, astrocytes, and oligodendrites.  Unipotent cells 
usually form only one cell type, that of the tissue of origin.  An example of unipotent stem cell is 
a skin stem cell which is only capable of differentiating into other skin cells. 
 
 
Adult Stem Cell Types 
 
 Adult stem cells (ASCs) can be found in different tissues in the adult, or in umbilical cord 
blood.  ASC’s are undifferentiated cells, living together with differentiated cells, residing in a 
tissue or an organ, and can usually differentiate only into the cell type of the specific tissue or 
organ they reside in (Kirschstein and Skirboll, 2009).  Although most studies show ACSs are 
unipotent, some studies show that certain types of ASCs can differentiate into cells other than the 
cells they are expected to produce, in a process called transdifferentiation (Kirschstein and 
Skirboll, 2009).  ASC’s primary function is the maintenance and repair of the tissue, and to 
replace the dead or unfunctional cells.  ASCs are important since their isolation does not destroy 
an embryo, so these cells typically have fewer ethical problems than ES cells.  However, ASC’s 
are very rare, thus it is very difficult to isolate these cells and grow them in cell culture to 
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produce large amounts for research or therapy.  It is also debatable whether ASCs are capable of 
providing the same long term therapy that ES cells can, so further research is needed.  Below is 
discussed some of the main types of ACSs.   
 
Hematopoietic Stem Cells (HSCs) 
 
Hematopoietic Stem Cells (HSCs) are responsible for forming all blood and immune cells 
(National Institutes of Health, Chapter 5).  HSCs have been studied for more than 50 years, 
therefore we know the most about this category of stem cell than any other.  Since 1957, HSCs 
have been used in human bone marrow transplants to treat patients with various types of cancer 
(Thomas et al., 1957).  Currently, about 40,000 HSC transplants are performed annually world-
wide (Horowitz, 1999).  
The most common source of HSCs is bone marrow, but they can also be obtained from 
peripheral blood if the person is first injected with hormones to stimulate their release from the 
bone marrow.  They are also obtained from umbilical cord blood, which has proven to be a rich 
source (Viacord, 2002).  Even though HSCs are the most well-known stem cell type, like every 
other adult stem cell they are very rare and hard to find: “The challenge is formidable as about 1 
in every 10,000 to 15,000 bone marrow cells is thought to be a stem cell. In the blood stream the 
proportion falls to 1 in 100,000 blood cells” (National Institutes of Health, Chapter 5). 
Studies show that there are two main types of HSC.  One type is called long-term  
because they are capable of renewing themselves repeatedly long-term, while the second type, 
short-term progenitor or precursor cells, cannot (Figure-1) (National Institutes of Health, 
Chapter 5).  For instance, “a blood progenitor cell may only be able to make a red blood cell”.  
Studies show that short-term progenitor cells can complete a cycle of hematopoiesis in about 
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three to four months, but scientists still do not know the exact time interval (Figure-2) (National 
Institutes of Health, Chapter 5).  From a therapy perspective, it would be best to isolate and 
perfuse only the true long-term HSCs.  “Unfortunately, to date, researchers cannot distinguish 
the long-term from the short-term cells when they are removed from the bloodstream or bone 
marrow”(National Institutes of Health, Chapter 5). 
 
 
 
 
 
 
Figure 1: Distinguishing Features of 
Hematopoietic Progenitor/Precursor Cells and 
Stem Cells. 
(http://stemcells.nih.gov/info/scireport/chapter4.asp) 
 
 
 
 
 
 Scientists continue to research the differences between HSCs taken from different 
sources.  HSCs taken in the earlier stages of development of an organism appear to be more 
effective in self-replicating and preventing subsequent immune system problems, “making them 
potentially more useful for therapeutic transplantation” (National Institutes of Health, Chapter 5). 
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Figure 2: Diagram of Hematopoietic and Stromal Stem Cell Differentiation.   
(http://stemcells.nih.gov/info/scireport/chapter5.asp) 
 
 
Neural Stem Cells 
 Neural Stem Cells (NSCs) are capable of regenerating portions of the human brain.  But 
their potency is still being debated.  Unlike most other ASCs, NSCs appear to be able to 
differentiate into different brain cells, including neurons, astrocytes, and oligodendrites (Figure-
3) (Brain Cancer Stem….2006).  It used to be believed that when a neuron is dead, or damaged, 
it was impossible to reverse the consequences, but scientists found this is not entirely true and 
some parts of the brain are capable of repair (National Institutes of Health, Chapter 8).  Studies 
indicate that NSCs “proliferate and migrate toward the site of the damage” (National Institutes of 
Health, Chapter 8) in order to repair damaged regions, and scientists are trying to harness this 
ability to treat neurodegenerative diseases and stroke.   
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Figure 3: Diagram of Neural Stem Cell Hierarchy.  
(University of Medicine and Dentistry of New Jersey, 2009) 
 
 
Mesenchymal Stem Cells  
 Mesenchymal stem cells (MSCs) are multipotent progenitor cells which are capable of 
differentiating into numerous kinds of other cells, such as bone, cartilage, and muscle cells 
(Figure-4) (National Institutes of Health, Chapter 4).  A common assumption was that MSCs 
could only be isolated from bone marrow, but recent studies show that MSC’s exist “in virtually 
all organs” (Meirelles et al., 2009).  Because of their ability to form multiple types of tissues, 
while not destroying an embryo to obtain them, MSCs have become one of the most highly 
researched type of stem cell in the past few years.  In spite of their relatively recent discovery, 
MSCs have already been used in bone marrow transplants, and “besides producing mature, 
specialized cells that interact with the HSCs, mesenchymal stem cells are also directly involved 
with regulation of the hematopoietic process” (Meirelles et al., 2009).   
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Figure 4: Diagram of Mesenchymal Stem Cell Differentiation.   
(http://stemcells.nih.gov/info/scireport/chapter4.asp) 
 
 
Cardiac Stem Cells  
 Cardiac stem cells (CSCs) are a relatively recent discovery.  Traditionally it was thought 
that heart tissue cannot regenerate.  But recent discoveries have found long-lived cells in heart 
tissue linings that can form new cardio myoblasts (Beltrami et al., 2003).  Therefore it is now 
believed that heart is capable of regenerating new tissue and can repair after being damaged. 
These cells appear to reside in the heart atrial wall (Figure-5), and scientists are trying to 
“mobilize these cells to regenerate cardiac tissue.  Better yet, researchers could perhaps stimulate 
cardiac stem cells already living in the heart to grow” (Touchette, 2003). 
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Figure-5: Diagram of the Isolation of Cardiac Stem Cells.  
(University of Pittsburg, 2009) 
 
 
 
Embryonic Stem Cells  
 
 Embryonic stem cells (ESCs) are the most medically valuable of all stem cell types, but 
unfortunately they are also the most controversial.  ESCs are capable of forming new ESCs long-
term which can provide large numbers of cells for therapy.  They also are capable of 
differentiating into all of human tissues except the placenta, and because of this unique ability, 
ESCs are the most important type of stem cell medically.  The embryos used to isolate ESCs are 
obtained from in vitro fertilization (IVF) (Figure-6, upper left).  Excess IVF embryos not 
required for reproductive purposes are donated for research by the parents with signed consent.  
The embryos are cultured for about 5 days to the blastocyst stage (diagram upper right).  The 
blastocyst is a hollow ball consisting of an outer trophoblast, and an inner cell mass (ICM). The 
ICM contains the ESCs.  Isolating the ICM usually destroys the embryo.   
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Figure-6: Diagram of the Isolation of 
Embryonic Stem Cells.   
(http://www.csa.com/discoveryguides/stemcell/
overview.php) 
 
 
 
 
 
 
 
 
Scientists are still trying to define the properties of ESCs, but according to the NIH they have the 
following properties (National Institutes of Health, Chapter 2):  
 Are derived from the inner cell mass/epiblast of the blastocyst.  
 Are capable of undergoing an unlimited number of symmetrical divisions without 
differentiating (long-term self-renewal).  
 Exhibit and maintain a stable, full (diploid), normal complement of chromosomes 
(karyotype).  
 Are pleuripotent cells that can give rise to differentiated cell types derived from 
all three primary germ layers of the embryo (endoderm, mesoderm, and 
ectoderm).  
 Are clonogenic: that is a single ES cell can give rise to a colony of genetically 
identical cells, or clones, which have the same properties as the original cell.  
 Express the transcription factor Oct-4, which then activates or inhibits a host of 
target genes, and maintains ES cells in a proliferative, non-differentiating state.  
 Can be induced to continue proliferating or to differentiate.  
 Lacks the G1 checkpoint in the cell cycle. ES cells spend most of their time in the 
S phase of the cell cycle, during which they synthesize DNA. Unlike 
differentiated [adult] cells, ES cells do not require any external stimulus to initiate 
DNA replication.  
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 Do not show X inactivation. In every [adult] cell of a female mammal, one of the 
two X chromosomes becomes permanently inactivated by X inactivation which 
does not occur in undifferentiated ES cells.  
 
 
Induced Pluripotent Stem Cells  
Unlike other types of stem cells, induced pleuripotent (iPS) cells do not occur naturally in 
the body, instead they are reprogrammed adult skin fibroblast cells.  Fibroblast cells are isolated 
from the skin of an adult, and are induced to de-differentiate to a pluripotent state by transfecting 
DNA encoding 2-4 transcription factor genes.  The transcription factors induce the cells to resort 
back to a stem like state from which they originated.  These cells appear to be as potent as ESCs, 
but they do not destroy an embryo, so they have become one of the hottest topics in all of stem 
cell research. 
 iPS cells were first isolated in Yamanaka’s lab in mice in 2006 (Vogel, 2006) using a 
technique that delivered 4 transcription factor genes to skin fibroblast cells (Oct4, Sox2, c-Myc, 
and Klf-4) (Figure-7).  These same four transcription factors were used in 2007 to convert 
human fibroblast cells to an ES-like state (Takahashi et al., 2007).  In 2008, it was found that 
using only two transcription factors could do the conversion, and it was especially important to 
leave out c-Myc as it caused the cells to divide uncontrollably (Kim et al., 2008).  In 2009, it was 
dicovered how to do the conversion using no transcription factors, instead using polyarginine 
proteins (Reprogramming..2009). 
Through reprograming and inserting reprogrammed genes, or using polyarginine 
proteins, scientists are trying to achieve the goal of preparing pluripotent stem cells for use in 
medicine, without all the ethical controversy (Kolata, 2007).  In fact, since iPS cells are induced 
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from an adult cell, the resulting ES-like cells are genetically identical to the patient, and should 
not be immuno rejected following the transplant. 
 
 
 
 
 
   Figure-7 - Induced Pluripotent Stem Cells.  
 (http://news.bbc.co.uk/2/hi/health/7101834.stm) 
 
 
 
 
 
 
 
 
 
 
Chapter Conclusion 
 
 Unlike common conceptions, all stem cells are not alike.  There are many different types 
of stem cells, with very different capabilities.  ES cells are the most potent and carry the best 
hope medically, but because they destroy an embryo they are the most controversial.  Thus 
scientists have been searching for substitute cells that do not destroy an embryo, such as adult 
stem cells, or even iPS cells.  Although ACSs can form tissues, their isolation is very difficult, 
and they are very hard to grow.  iPS cells likely offer the best long-term solution since they 
appear to be pluripotent, and can be induced from a skin fibroblast cell, so it is possible to 
prepare an ES cell line genetically identical to a patient which would avoid immuno-rejection. 
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CHAPTER-2:  STEM CELL APPLICATIONS 
Anvar Niyetkaliyev 
 
 
Chapter 1 discussed the various types of stem cells and their sources.  In this chapter, the 
discussion of stem cell technology continues by investigating what stem cells have been used for.  
Various types of stem cells have been used to treat complicated diseases such as blood cancers, 
damaged heart muscle, diabetes, spinal cord injuries, Parkinson’s disease, and others, either in 
animal models or in humans.  Describing stem cell medical applications serves as an introduction 
to the Chapter-3 discussion of stem cell ethics, and allows the delineation of which applications 
remain in animal experimentation, versus those that have proceeded to human clinical trials. 
 
Hematopoietic Stem Cell Applications 
Hematopoietic stem cells (HSC) are the most researched type of stem cells.  Scientists 
have more than 50 years of experience using HSCs to treat different types of blood diseases, 
especially treating cancer patients recovering from chemotherapy and radiation to re-establish 
their blood cell system.  Chemotherapy destroys rapidly dividing cancer cells in the body, but it 
also destroys a patient’s rapidly dividing blood cells and HSCs, which constitute the immune 
system.  Doctors may give patients HSC transplants to restore the immune system.  HSCs are 
traditionally isolated from a patient’s bone marrow, then they are stored while the patient 
undergoes intensive cancer therapy.  Once the chemotherapy drug has been eliminated from the 
patient’s body, he or she gets a transplant of his or her own stored HSCs, or from a 
histocompatible donor if one can be found (Hematopoietic Stem Cells, 2005).  One problem with 
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HSC transplants is the cells are sometimes contaminated with cancer cells which then get 
perfused back into the patient.   
Table I shows a list of various diseases treated with HSCs using either autologous 
transplantation with the patient’s own stem cells (left side of table), or allogeneic transplantation 
with an HLA matched donor (right side of table).  Approximately 30, 000  autologous and 15, 
000 allogeneic transplant procedures are performed yearly world wide (Powell, 2008). 
 
Autologous Transplantation Allogeneic Transplantation 
Malignant Disorders 
Nonmalignant 
Disorders 
Malignant Disorders Nonmalignant Disorders 
 Neuroblastoma  
 Non-Hodgkin 
lymphoma  
 Hodgkin disease  
 Acute myeloid 
leukemia (AML)  
 Medulloblastoma  
 Germ-cell tumors  
 Multiple 
myeloma* 
Autoimmune 
disorders  
Amyloidosis 
 AML  
 Non-Hodgkin 
lymphoma  
 Hodgkin disease  
 Acute 
lymphoblastic 
leukemia (ALL)  
 Chronic myeloid 
leukemia (CML)  
 Myelodysplastic 
syndromes  
 Multiple 
myeloma*  
 Chronic 
lymphocytic 
leukemia* 
 Aplastic anemia  
 Fanconi anemia  
 Severe combined 
immunodeficiency  
 Thalassemia major  
 Diamond-Blackfan 
anemia  
 Sickle cell anemia  
 Wiskott-Aldrich 
Syndrome  
 Osteopetrosis  
 Inborn errors of 
metabolism  
 Autoimmune 
disorders 
  Table I.  A List of Diseases Treated With Autologous and  
  Allogenic Type Bone Marrow Transplants (Powell, 2008). 
 
 
 
Table II shows the survival rate of children with different illnesses following treatment 
with HSCs.  For allogeneic transplantation, the data is stronger for a sibling donor compared to 
an unrelated donor. 
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Disease Stage Survival Rate (%) 
Autologous 
Transplantation 
Allogeneic 
Transplantation 
Sibling 
Donor 
Unrelated 
Donor 
Acute lymphoblastic 
leukemia (ALL) 
Complete response 
(CR)1 
N/A 65 45 
CR2 N/A 55 35 
Acute myeloid leukemia 
(AML) 
CR1 60 65 30 
CR2 40 45 50 
No remission 20 N/A 25 
Chronic myeloid leukemia 
(CML) 
Chronic phase <1 y N/A 70 55 
Chronic phase >1 y N/A 60 50 
Hodgkin disease CR1 80 N/A N/A 
CR2 70 N/A N/A 
No remission 45 N/A N/A 
Diffuse large-cell 
lymphoma 
CR1 65 25 30 
50 25 N/A 
45 20 N/A 
Neuroblastoma 40 N/A N/A 
  Table II.  Survival Data for Various Diseases  
  Following HSC Transplants (Powell, 2008). 
 
 The literature documents many personal cases of individuals treated with HSCs.  
Recently, in Leeds UK, Sophie Edward, an 8 year old, was found to have a rare form of 
leukemia, acute lymphoblastic. Chemotherapy was performed to kill cancer cells, then doctors 
transplanted bone marrow tissue.  After 3 months Sophie fells much better (Amitava, 2009). 
 In 2008, a Colombian citizen became famous for her windpipe treatment.  Her windpipe 
leading to the left lung was damaged dramatically in an accident, and 30 year old Claudia 
Castillo could barely breathe.  In Barcelona, doctors found a donor from which a cartiledge 
scaffold could be taken.  Researchers at the University of Bristol took HSCs from Castillo’s bone 
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marrow and used them to coat the windpipe scaffold.  The new organ was transplanted in June 
2008 safely in Barcelona. The surgery went successfully, and 6 months later the world saw that 
she was fine and her breaths were normal.  Figure-1 shows a computer simulation of the 
windpipe before (left) and after (right) surgery.  This case demonstrates the huge potential HSCs 
have for future research (Coghlan, 2008). 
  
  Figure 1.  Computer Simulation of the Windpipe Surgery Before (left)  
  and After (right) HSC Transplantation (Coghlan, 2008). 
 
 
Stem Cell Treatment of Diabetes 
Of the millions of people who suffer from diabetes, nearly 5-10% have type-1. This type 
of diabetes usually occurs as a result of autoimmune destruction of pancreatic islet β-cells, which 
normally produce insulin.  The disruption of insulin production requires exogenous insulin 
intervention.  Although some success has been achieved with islet transplants, the severe 
shortage of pancreas donations has caused researchers to seek alternative sources for β-cell 
substitution therapy.  
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Pluripotent embryonic stem (ES) cells have been shown to have the potential to 
differentiate into insulin producing cells.  Animal ES cells have been shown to differentiate into 
insulin producing cells either in vitro or in vivo.  Transplant experiments with human ES cells 
have not yet been performed, but human ES cells have been shown to have the potential to 
produce insulin.  The in vitro-differentiated hES cells included the generation of  insulin-making 
β-cells (Assady et al., 2005). Immunohistochemical spotting for insulin was discovered in an 
astonishingly high percentage of the differentiated cells.  Thus, hES cells might be used in the 
future to treat diabetes (Assady et al., 2005). 
Adult stem cells have had some success treating diabetic patients.  In 2007, in the UK 15 
patients with Type-1 diabetes volunteered to participate in a human clinical trial to use HSCs to 
treat the disease.  After the injection of HSCs, the patients were able to get rid of their needles 
and pills to control sugar and diabetes.  The successful results were fascinating to scientists all 
over the world, as it appeared that the HSCs had the plasticity to differentiate outside the blood 
cell lineage to produce β-like cells.  One patient was completely cured.  Two patients required 
insulin injections for an additional year, but eventually put aside pills and injections (Times 
Online, 2007). 
 
Stem Cell Treatment of Damaged Heart Muscle 
Heart muscle cells (cardiac myocytes) are the contractile cells of the heart, and can 
become damaged after a heart attack or an accident.  Heart attacks leave scars in place of 
contractile tissue.  Currently in the United States, about 5 million citizens live with damaged 
hearts, and each year about 400,000 new cases appear (NIH, 2009).  Heart transplants have been 
successful in some cases, but they are expensive and donated hearts are in short supply.  
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Transplants using cardiac myocytes have been attempted, but the transplanted cells rarely 
become contractile.  Thus, scientists are searching for stem cell treatments to repair wounded 
hearts.   
In 2009, doctors with the help of scientists healed a patient’s heart using his own cardiac 
stem cells.  Kenneth Miles, a construction worker had a heart attack at age 39 on the left side of 
his heart.  Doctors located the exact position of scars on the heart and excised them.  Adult 
cardiac stem cells were removed from the patient’s heart, cultured at Cedars Sinai Hospital, and 
perfused back into the patient where they became contractile  (Ani, 2009). 
A very interesting case happened in 2003 with 16 year old Dmitri Bonnville.  He 
accidently shot himself in his heart when doing some home repairs. While undergoing surgery, 
Dmitri had several heart attacks, and some of his cardiac myocytes were damaged. Surgeons 
stated that heart transplantation was needed immediately to save him, but a donor was not 
available so doctors offered a medical treatment never done before using the patient’s own bone 
marrow HSCs cells.  They said that adult stem cells would be taken from his bone marrow (or 
from hormone stimulated blood) and injected into his heart to repair it.  Dmitri’s parents agreed, 
and the results were exciting, the harvested stem cells reached the damaged part of the heart and 
appear to have replaced the dead cells.  This kind of experiment used adult HSCs without 
destroying an embryo, and strengthened the evidence for HSC plasticity (Philipkoski, 2003). 
 This approach of using a patient’s own HSCs to treat heart attacks subsequently 
underwent a larger trial at the University of Bristol, where 60 heart attack patients received HSCs 
from their own bone marrow.  The trial was of low risk since the grafts were autologous.  In 2-3 
months, most patients’ hearts fully recovered and worked properly. This clinical trial was lead by 
Doctor Raimondo Ascione using a grant of £210,000 (Science Daily, 2007).  Thus adult HSCs 
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have shown some clinical success in treating heart attacks.  With respect to ES cells, although 
human ES cells have not yet been tested for heart attack treatments, they have been shown to be 
capable of differentiating in vitro into cardiac lineages (Kehat et al., 2001). 
 
Stem Cell Treatment of Spinal Cord Injuries 
 With respect to treating spinal cord injuries, most of this data so far is based on animal 
experimentation.  In 2008, approximately 300,000 people in the US had spinal cord injuries 
(SCI) (FSCIP, 2009).   In a recent 2009 article, the US Food and Drug Administration permitted 
scientists to perform a clinical trial with ES cells treat 10 SCI patients (Shoute, 2009).  After 
years of studying similar tests on rats and mice, doctors decided it was time to test the therapy on 
human beings.  Each patient had injuries located close to the neck. The experiment is still in 
phase I, and no data has been reported.  If everything goes well with respect to phase I safety, 
scientists will proceed to phase II to determine effacacy (Shoute, 2009). 
 Adult stem cells have also been tested for spinal cord injuries, but the results have not 
been published in the refereed literature yet.  In Ecuador, 52 patients with SCI were injected with 
their own autologous bone marrow HCSs, and the outcomes were successful.  Doctor Silva 
stated the following:  
“To date, we have administered BMCs into 52 patients with SCI, and 
have had no tumor formations, no cases of infection or increased pain, 
and few instances of minor adverse events. We also found that the 
patient quality of life improved” (Don Margolis 2009). 
 
Stem Cell Treatment of Parkinson’s Disease 
 One of the major diseases of the brain is Parkinson’s disease (PD).  In this disease, 
neurons in the substantia nigra area of the brain become damaged, and are unable to produce an 
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important neurotransmitter dopamine.  Without dopamine production, patients show multiple 
types of muscle tremors, and difficulty initiating movements.  A well known professor from 
UCLA, Michel L. Levesque, testified before the US Senate on a Parkinson’s case that he treated 
using olfactory mucosal stem cells (Levesque, 2005).  In 2005, at the Congress of PD and 
Movement Disorders in Rome, Dr. Levesque introduced the results of his 3 year experiment 
using autologous and derived adult stem cells: 
“In accordance with our institutional review board, we transplanted a 
patient with advanced Parkinson’s disease with differentiated neurons 
derived from an initial needle biopsy. At three years post-operatively, 
the overall Unified Parkinson’s Disease Rating Scale (UPDRS) 
improved by 81% while “on” medication and 83% while “off” 
medication. We demonstrated here the long-term clinical remission of 
Parkinson’s disease symptoms in a single patient.” (Levesque, 2005) 
 
 Rat models of PD have been treated with adult NSCs (Studer et al., 1998).  Adult neural 
stem cells (NSCs) are extracted from the brain and are expanded in vitro, then are injected back 
into the brain to form dopamine producing neurons.  The injected cells did not form brain 
tumors, and produced dopamine.   Rat and mouse PD models have also been treated with ES 
cells (Bjorklund et al., 2002; Kim et al., 2002; Ryan, 2004).  For example, one experiment took 
place in UK in 2004 where human ESCs were injected into 10 PD mice. The outcome showed 
that no tumors appeared, and the neural systems improved in 12 weeks (Ryan, 2004).  Human ES 
cells have not yet been used to treat PD patients, but have been shown in vitro to be capable of 
differentiating into dopamine producing neurons (Perrier et al., 2004). 
 
Chapter-2 Conclusions  
 As can be seen in the discussions above, some types of stem cells have already been used 
to save human lives, while in other cases human applications remain in the future. Scientists all 
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over the world are trying to adapt stem cell treatments for various diseases. This chapter focused 
on several example applications, and attempted to distinguish animal experimentation from 
human trials.  Successful experimental outcomes in human patients can sometimes sway the 
debate on stem cell ethics and legalities, which will be discussed in the next two chapters.  More 
research is needed to adapt stem cell treatments to a greater number of diseases, and to adapt the 
findings from animal models to humans.  Each year, new applications have saved lives under 
conditions where no other medical treatments help. 
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CHAPTER 3: STEM CELL ETHICS 
Batuhan Gizer 
 
 In the previous chapters we discussed various stem cell types, their potencies, and how 
they have been used in animal models and some human studies to cure or prevent some of the 
deadliest illnesses.  In this chapter, we will discuss the topic of whether we should work with 
stem cells, explaining the ethics surrounding stem cells.  As not all stem cells are alike, each type 
has different ethics to apply.  With respect to embryonic stem (ES) cells, because their 
acquisition usually destroys an embryo, a discussion of their ethics usually focuses on when life 
begins.  This chapter will investigate various religious stances on this topic. 
 
Adult Stem Cell Ethics 
 Adult stem cells (ASC’s) are the stem cell type with the fewest ethical considerations, 
because no embryo is destroyed to obtain them.  In fact, none of the five major world religions is 
against working with ASCs.  Even the conservative Catholic church, which is strongly against 
working with ES cells, is in favor of ASCs (American Catholic Organization, 2006; Pope 
Benedict XVI, 2007).  The other major world religions, Islam, Judaism, Hinduism, and 
Buddhism, also do not have any problems with ACS research, especially if human lives can be 
saved.  In fact, most religions go beyond merely allowing ASC research, and actually strongly 
support it as an alternative to destroying embryos in ES cell research.   “Perhaps research using 
stem cells derived from adults will eventually prove to be most promising. We should encourage 
further research on the use of adult stem cells, to the point where it will be unnecessary to use 
embryos for this purpose. Specifically, we should find better ways to isolate existing stem cells 
 29 
in the human body” (Kutty and Siddiqi, 2007).   However, as explained in the previous chapters, 
ASC’s are not as medically promising as ES cells because they are very rare in the body, difficult 
to isolate, and hard to grow in culture, so most scientists keep pushing to allow federal funding 
for ES cell research. 
 
Embryonic Stem Cell Ethics 
 All religions in the world value human life, and believe that human life is very precious.  
Even before the current discussions for embryonic stem cell research, public debates occurred on 
topics such as the fate of surplus in vitro fertilization (IVF) embryos, and the destruction of an 
embryo in the womb for abortion.  Thus, debates about human embryos have been in the picture 
since the early 1970’s with the advent of IVF clinics (Edwards, 2001).   Because obtaining ES 
cells usually destroys an embryo, the debate focuses on when life begins.  If life is considered to 
start at conception, isolating ES cells from a 5-day old blastocyst is considered to be murder, 
however if a religion argues life begins at day 40 (or thereafter), early embryos do not have the 
same moral status as an adult, and can be used to obtain ES cells. 
 
Catholic Point of View on ES Cells 
 The strong opposition of the Catholic church to embryo destruction is well known.  On 
July 23, 2001, Pope John Paul II, strongly condemned ES cell research, with the following words 
to then U.S. President George W. Bush: “Experience is already showing how a tragic coarsening 
of conscience accompanies the assault on innocent human life in the womb, leading to 
accommodation and acquiescence in the face of other related evils such as euthanasia, infanticide 
and, most recently, proposals for the creation for research purposes of human embryos, destined 
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to be destroyed in the process” (Pope John Paul II, 2001).  And as subsequently stated by Pope 
Benedict:  human embryonic stem cell research, artificial insemination, and the possibility of 
human cloning have "shattered the barriers meant to protect human dignity”,… Benedict said the 
Roman Catholic Church wants scientific progress to be based on "ethical-moral principles," 
including respect for human beings "from conception until natural death” (Pope Benedict XVI, 
2007).  And Pope Benedict went further to state that he church "appreciates and encourages" 
stem cell research that does not involve the destruction of a human embryo” (Pope Benedict 
XVI, 2007). 
 Outside the Catholic church, several other Christian denominations are in favor of ES cell 
research.  For example the American Presbyterian Church believes that ES cell research is 
ethical if it results in new medical therapies (Teaching About Religion, 2006), and the Episcopal 
church believes life begins 14 days post-fertilization when the primitive streak begins to form the 
spinal cord (Kohsl, 2008). 
 
Judaism Point of View on ES Cells 
 Jewish law attests that life does not begin at conception, but once the fetus has the means 
to become a viable embryo, which is usually considered around day 40.  Therefore Jewish law 
has no opposition to harvesting early day-5 embryos for research (Dorff, 2001). 
 
Islamic Point of View on ES Cells 
 Islamic belief is based upon “divine and immutable revelation”, the main authority of 
Muslims known as the Qur’an, and none of the Islamic literature indicates any opposition against 
ES cell research, as long as it is used to better humanity (Weckerly, 2002).  Shari’ah is a way of 
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life for Muslims, interpreted from the Qur’an, indicating the laws and the necessities of Islam to 
influence their actions and thoughts.  The Qur’an indicates that God creates life, and the time is 
given in the Qur’an as 120 days, life occurs “first as a drop of matter in forty days, then as a 
blood clot for forty days, then as a blob for forty days, and then the angel is sent to breathe life 
into him” (Weckerly, 2002).  We can clearly see from these words that a 5 day blastocyst from 
which ES cells are obtained, are not considered as a human being yet since it is younger than 120 
days. 
 In addition, the Shari’ah dictates that there should be a distinction between potential and 
actual life.  Although it is believed that an embryo has the potential to grow into a human being, 
it is not an actual human, and instead of destroying excess embryos taken from IVF clinics, those 
embryos should be used to help better the conditions of actual life  (Siddiqi, 2002).   Thus, the 
main difference between the Islamic and Christian perspectives on stem cells is when life begins, 
and when the embryo has potential not actual life. 
 
Buddhist Point of View on ES Cells 
 Buddhists believe that three things are necessary to begin a human life.  First, a woman’s 
egg is required to form an embryo.  Second, a man’s sperm must fertilize the woman’s egg.  And 
lastly, “consciousness of being ready for rebirth” is required for the rebirth of a human being, 
explained as karma-energy or a soul (Mahathera, 1994).  So if consciousness occurs at 
conception, a 5-day embryo is living.  And Buddhism also is against in vitro fertilization, 
because it is believed that an artificial process is against the nature of humanity.  ES cell research 
is prohibited because Buddhists believe that any action related to harm is immoral, hence it 
should be forbidden.  “Rebirth” of a human being can be the rebirth of an old karma-energy, or 
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soul, or an embryo can be a new soul, therefore it should be considered and treated as a human 
(Chamany, 2004). 
 
Parthenote Ethics 
 Due to the strong opposition by many people against ES cells, scientists are looking for 
new ways to derive ES cells without destroying an embryo.  The parthenote technique is one of 
these new ways that does not kill a viable embryo yet is able to retrieve ES cell lines.  
Parthenogenesis, or virgin birth, is used by some insect species such as bees and ants to produce 
worker animals.  In this case the new worker bees or ants grow from non-fertilized eggs 
stimulated to divide by a female.  Human parthenote embryos were first produced in 2001 
(Cibelli et al., 2001), by treating donated eggs with chemicals (such as strontium chloride) to 
stimulate egg division without chromosome loss.  No sperm is used in the process.  However, 
human parthenote embryos cannot develop into a human due to the lack of paternal DNA, but 
are able to form “embryo-like” entities (Latkovic, 2006).  If the embryo can be grown to the 
blastocyst stage, ES cells could be isolated to make an ES cell line, without destroying a viable 
embryo.  However, using this process still requires human egg donations, and it is not clear 
whether human parthenote ES cells will prove as potent as normal ES cells.   
 Parthenote ethics focuses on the status of an embryo that cannot form a human.  Some 
people argue that it cannot be defined as a normal embryo since the process does not involve a 
human sperm, which in my opinion is a valid point.  Some religions claim that using parthenotes 
is still immoral.  Some Catholics are against it because the embryo may still have the potential to 
make life, we just haven’t figured out how to do so yet, and it still involves the destruction of a 
human egg.  Buddhists oppose the idea because they believe fertilization should be natural, and 
 33 
should not involve any chemical substance (Kiessling, 2005). 
 
iPS Cell Ethics 
 iPS cells are induced pluripotent cells obtained from skin fibroblast cells by treating them 
with a mixture of transcription factors to induce de-differentiation to an ES cell like state 
(Takahashi et al., 2007).  No embryo is destroyed in the process, and the ES cell line is 
genetically identical to the patient the skin cells were obtained from, so the ES cells will not be 
immuno-rejected during transplant back into the same patient.  This topic is the hottest topic in 
all of stem cell biology today, as these cells could potentially replace ES cells derived from 
embryos if iPS cells are shown to be as potent as ES cells. 
 
Chapter-3 Conclusions 
 As shown in this chapter, Catholics and Buddhists oppose ES cell research since it is 
believed that killing a 5-day old embryo constitutes murder, but Muslims and Jews do not since 
it is believed that life starts at day forty, well after the period of time when blastocysts is 
retrieved.  All major world religions support adult stem cell research. Since ES cell research is 
highly controversial, scientists are constantly researching new ways to derive ES cell lines 
without harming or using an embryo, such as iPS cells.  I believe that ES cell research should be 
federally funded and expanded, because I believe that an embryo can help save hundreds of 
thousands of lives.  Excess IVF embryos slated for destruction should be used with donor 
consent to derive new ES cell lines.  Although adult stem cells can be helpful, they are not as 
medically promising as ES cells.  The research should be carefully controlled to prevent 
unethical use of paid egg donors, and to ensure only excess IVF embryos originally created for 
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reproduction are used.  I do not believe that paid egg donors should be allowed because this 
might harm innocent people if others forced them to do so in order to be paid.  This occurs rather 
frequent in third world countries that are not economically strong.   If paid egg donors are 
allowed, in my opinion, they should be controlled and protected.  In our world, organ donations 
are insufficient to save the lives of thousands of patients awaiting transplants, so ES cells could 
in theory alleviate the shortage of transplant tissues.  
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CHAPTER-4:  STEM CELL LEGALITIES 
Anvar Niyetkaliyev 
 
 
Nowadays it would be hard to find a more controversial topic than stem cells.  As 
discussed in previous chapters, although adult stem cells (ASCs) have relatively few ethical 
issues, as obtaining them does not use an embryo, embryonic stem (ES) cells are far easier to 
isolate, can be grown to large quantities in vitro, and are far more potent for repairing a variety of 
tissues.  Scientists have already proven several applications for stem cells in saving lives, but 
more research needs to be performed to expand the number of diseases that can be treated with 
this new technology.  And this takes money. Typical of controversial scientific discoveries, laws 
have been enacted to regulate this new science.  The purpose of this chapter is to discuss past and 
current US and international stem laws, as an example of the effects of technology on society. 
U.S. Federal Stem Cell Laws 
 
Within the US, stem cells laws have varied over the years, depending on which President 
is in office.  Usually laws change when a new President is elected in January every four years.  
From one President of the United States to another, the regulations governing stem cell research 
have changed dramatically.  
 
President Clinton Stem Cell Policies 
Former President Clinton was a strong advocate for stem cell research.  In 1993, 
Congress and President Clinton gave direct authority to the National Institute of Health (NIH) to 
fund human embryo research for the first time.  NIH established a multi-background panel to 
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investigate stem cell ethics, which made a recommendation to use excess IVF embryos (normally 
discarded with parental consent) to derive new ES cell lines.  However,  within a year, opponents 
lobbied congress to pass the now famous Dickey-Wicker Amendment  which banned federal 
funding to create or destroy any human embryo (Stem Cell Laws, 2005).   
 In January 1999, Harriet Rabb of the Department of Health and Human Services (HHS) 
released a legal opinion that ES cells are not embryos, so the Dickey-Wicker Amendment should 
not apply to those cells.  In response to the amendment, in August 2000, the NIH published 
guidelines recommending federal funding only for research on previously derived ES cells 
(Dunn, 2005).  President Clinton quickly endorsed the guidelines to become the first 
administration to fund ES cell research.  
 
President Bush Stem Cell Policies 
In 2001, in his State of the Union Address, newly elected President Bush laid out his 
views on embryo research, recommending that Congress pass legislation prohibiting all embryo 
research, and telling NIH to cancel all new federal applications on that topic (Agnew, 2003).  On 
August 9
th
, 2001, Bush announced he would allow federally funded research only on human ES 
cell lines derived prior to that date (Stem Cell Laws, 2005).  Scientists rushed to determine how 
many ES cell lines they could work with, and came to realize the initial high numbers were a 
vast overestimate, as subsequent research showed the majority of the lines died or were non 
functional.  The actual number of useful ES cell lines has varied tremendously depending on the 
source of information, but one source estimated that out of an original guess of 71 eligible lines, 
only four  were immortal, a number which most scientists agree is far too low to support a 
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serious research effort (Holden, 2009).  Other references have the numbers as 60 total and 9 
functional cell lines (Agnew, 2003). 
 In 2002, Bush created his own Council of Bioethics to provide advice on embryo 
research, choosing on purpose not to use any well-established scientific organizations, such as 
the NIH, National Academy of Sciences, or the American Society for Bioethics and Humanities.  
In April 2004, 206 members of the House of Representatives signed a letter explaining the need 
to expand the number of ES cell lines, and in June, 58 Senators sent Bush a similar letter, but 
Bush’s position did not change.  Bush would later veto any attempt by Congress to overturn his 
restrictions. 
 Throughout the Bush administration, debates often focused on the term “cloning”, but 
this term was vastly misunderstood by the public.  Most opponents viewed “cloning” as 
reproductive cloning, in which a complete organism genetically identical to another is produced.  
This process has scientifically only been achieved with animals (such as Dolly the sheep), 
involves the use of somatic cell nuclear transfer (SCNT), and remains outlawed to this day in all 
countries who bother to pass embryo legislations.  Therapeutic cloning, involves the use of 
SCNT to create a blastocyst to derive new ES cell lines for treating the same patient that the skin 
cell nucleus came from.  This process has also been achieved with animals, but not yet with 
human cells.  Note that the derivation of ES cells from IVF embryos does not involve any SCNT 
(Angew, 2003).   Under the Bush administration with its tight stem cell policies compared to 
other developed countries, some scientists argued that unless the ban was soon over turned, US 
research would suffer. 
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President Obama Stem Cell Policies 
 
On March 9, 2009, newly elected President Barack Obama, acting on a new set of NIH 
guidelines (Mahumder and Cohen, 2009; Holden, 2009), over turned the Dickey-Wicker 
Amendment and Bush’s 2001 stem cell policy, to create a new stem cell policy that allows 
federal funding to support embryo research, so long as the embryos are provided by IVF clinics 
originally created for reproductive purposes, and with donor consent, and no money can be paid 
for egg donors.  Obama stated:   
“Research involving human embryonic stem cells and human non-
embryonic stem cells has the potential to lead to better understanding 
and treatment of many disabling diseases and conditions. Advances 
over the past decade in this promising scientific field have been 
encouraging, leading to broad agreement in the scientific community 
that the research should be supported by Federal funds. For the past 8 
years, the authority of the Department of Health and Human Services, 
including the National Institutes of Health (NIH), to fund and conduct 
human embryonic stem cell research has been limited by Presidential 
actions. The purpose of this order is to remove these limitations on 
scientific inquiry, to expand NIH support for the exploration of human 
stem cell research, and in so doing to enhance the contribution of 
America’s scientists to important new discoveries and new therapies 
for the benefit of humankind.” (National Archives and Records 
Administration, 2009) 
 
The NIH Guidelines underwent considerable deliberations before their final approval in 
2009.  The use of IVF embryos allows significantly more ES cell lines to be derived, without 
resorting to the more controversial method of paid egg donors.  The informed consent applies to 
fertilized embryo donors, not to individual gamete (sperm or egg) donors.  Much effort focused 
on whether to “grandfather in” old ES cell lines, with the final recommendation being no 
grandfathering, and instead any ES cell line must be individually approved by NIH, including 
any ES cell lines previously approved by the Bush administration.   The NIH guidelines do not 
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allow the use of embryos created for research purposes, such as SCNT or parthenogenesis, which 
was a disappointment for some scientists including Kevin Eggan of Harvard University, but 
overall, it seems that researchers are happy with the newly established rules and are ready for 
new progress in stem cell research George Daley, a stem cell researcher at Harvard University, 
described the new rules as “a major step in the right direction for stem cell research” (Holden, 
2009).     
 
Although most scientists are happy with the new guidelines, some argue that the 
guidelines from the National Academy of Science (NAS) (Table I) should have been the gold 
standard for the conduct of stem cell research in the country (Mahumder and Cohen, 2009). 
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Table I.  A Comparison of NIH and National Academy of Sciences Stem Cell 
Guidelines.  (Mahumder and Cohen, 2009) 
 
 
 Some scientists feel the new guidelines are too conservative, and efforts should be made 
to expand the use of egg donors.  The International Society for Stem Cell Research (ISSR) urged 
NIH to begin “open discussions on funding research carried out with human pluripotent stem cell 
lines derived from sources other than excess reproductive IVF embryos” (Holden, 2009).   
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U.S. State Stem Cell Laws 
 
 In the US, individual states can provide their own funding for stem cell research, even 
when federal funding is not allowed.  State policies were especially of strong importance under 
the Bush administration 2001 ban of federal funding.  Some states such as Illinois and South 
Dakota completely prohibit embryo research for any reason, while other states like New Jersey 
and California not only permit scientists and institutions to work on ES cells, they also create 
huge funds to support the research.   
 After the 2001 ban on federal funding, six states encouraged support by providing much 
needed funds: California, New York, New Jersey, Massachusetts, Virginia, and Illinois. Other 
states have various laws, for example Pennsylvania state law prohibits experiments on fetuses 
and embryos, and  in North Dakota it is illegal to use SCNT (Stem Cell Legislation, 2005).   
Over the years, other states have even changed their views and have started to fund the research. 
  The first two states that took a big step in supporting stem cell research were New Jersey 
and California.  In November 2004, California voted to approve a fund of $ 3 billion dollars for 
stem cell research and to create the California Institute of Regenerative Medicine (CIRM).  $622 
million has already been issued for 2008 and 2009.  Due to delays in California with the funding, 
New Jersey was actually the first state to fund stem cell research, creating the New Jersey Stem 
Cell Institute.  The state supports 17 institutions with $23 million in 2005 and 2006.   
With respect to other states, Connecticut has passed a bill in 2005 providing $10 million 
over several years. The Illinois governor, looking at improvements in biomedicine in other states, 
decided to fund the Illinois Regenerative Medicine Institute with $10 million for research.  In 
two years a new bill has passed saying that the research is permitted on any of stem cells.  
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Indiana legislators approved funding to hire stem cell instructors.  Maryland has followed its 
neighbors and approved legislature to open the Maryland Stem Cell Research  (NCSL, 2008).  
 
International Stem Cell Laws 
  
 Although the study of embryonic stem cells is a very important area in biomedicine, 
nations across the world have completely different laws and regulations on ES cell research. 
International policies range from progressive (Sweden, England, China, Australia), moderate 
(US, Canada), to non-existent (Italy, Germany, France, Saudi Arabia).  The author of this chapter 
believes that Sweden, UK, China and Canada are the most committed to supporting stem cell 
research.  The stem cell policies from some example countries will be discussed below. 
 
Sweden  
 
In 2002, Sweden was a leader in stem cell research because it established a Stem Cell 
Bank with $1 million and already had 9 institutions performing stem cell research with about 300 
research groups.  Sweden had advantages over other leading countries such as support of the 
public, committed scientists, and sufficient funding from the government. Also Sweden has 
enormous experience with ES cells; Professor Patrick Brundin has used ES cells for over 15 
years to treat patients with Parkinson’s disease (Sweden’s Stem Cells Success, 2002). 
 
The European Union 
 
 The European Union has provided a proposal for funding ES cell research for European 
countries with a budget of $64.3 billion for the years 2007-2013.  However, this proposal has 
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created disagreement between EU nations because each has different regulations.  Germany and 
several other EU countries are against all embryo research, and worry only those countries that 
support embryo research would receive any of the funding. In 2006, the German research 
minister Annette Schavan stated that "the European Union science program should not be used to 
give financial incentives to kill embryos" (Deutsche Welle, 2006). 
South Korea 
 
  For South Korea, research on stem cells is a key for their future.  In 2005, Korean 
researcher Hwang was the first to claim success preparing human ES cell lines by SCNT (Hwang 
et al., 2005), one of the holy grails of stem cell research, because that technique would allow ES 
cells to be prepared that are genetically identical to a patient, however that paper was 
subsequently retracted for fraud.  But the Koreans are still world class in embryo research, and 
have progressive policies that allow SCNT and paid egg donors. In 2005, Korea approved a stem 
cell bank that will provide researchers worldwide with ES stem cell lines.  During the Bush 
administration ban on federal funding, the Korean lines were a huge benefit for U.S scientists 
(Kaplan, 2005).  
 
Chapter-4 Conclusion 
 Although stem cells have the potential to save countless lives from various diseases, 
scientists willing to research these cells are not enough, governments should support this 
research and enact laws to legalize embryo research.  This chapter demonstrates that stem cell 
laws vary greatly internationally, and people’s attitudes towards stem cells change regularly.  
With the support of nations, brilliant scientists, federal funds, and proper laws, the goal of saving 
human lives using stem cells can be reached. 
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PROJECT CONCLUSIONS 
 
 
 Due to the very strong medical potential of using embryonic stem (ES) cells, we think 
that scientists and doctors should continue to work with these cells to achieve their fullest 
benefits to society.  Based on our research, this new technology is quite promising, and with 
proper regulations to tightly govern embryo donors, ES cells can save thousands of human lives. 
We support the idea that the blastula being destroyed to obtain ES cells has less moral status than 
the thousands of “fully individualized” adult and children lives that would be saved.  Adult stem 
cells (ASCs) should be used whenever possible as an alternative source to ES cells, because they 
have already been shown to cure some types of injuries and illnesses, but we agree that ASCs 
may not work for all diseases.  All 5 major world religions support the use of ASCs.  When 
deriving new ES cell lines, we agree with the progressive legislations in countries such as 
Sweden and South Korea, that allow egg donors to be paid.  In the U.S., Obama’s recent change 
in the government policies to allow federal funding of ES cell research should positively impact 
the field of stem cells.  We conclude that more research should be performed to help expand the 
list of treatable diseases using stem cell technology.  
 
 
